Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) and keeping the price target at ...
After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured ...
Quoin Pharmaceuticals (QNRX) announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome. In December 2024 ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan ...
(RTTNews) - Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Thursday, announced additional clinical data supporting the efficacy of its investigational ...
Quoin Pharmaceuticals has announced new clinical data indicating the need for ongoing treatment with QRX003 for patients with Netherton Syndrome, as all positive effects observed during a 12-week ...
Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company ...
In a turbulent market environment, QNRX stock has reached a new 52-week low, trading at just $0.42. According to InvestingPro data, while the company maintains a FAIR financial health score and holds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback